cells

Lung Cancer Clinical Trials

Non-Small Cell Lung Cancer, PD-L1 Positive (ARC-7)

Overview

A Phase 2 randomized, open-label trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant in front-line non-small cell lung cancer.

Key Eligibility Criteria

  • Histologically confirmed squamous or nonsquamous, PD-L1 positive, non-small cell lung cancer that is locally advanced or metastatic
  • No sensitizing EGFR or ALK mutation expression

ARC-7 Clinical Trial Locations

clinicaltrials.gov

arrow

Non-Small Cell Lung Cancer, PD-L1 Positive (ARC-10)

Overview

A randomized Phase 3, open-label, study to evaluate the efficacy of zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with domvanalimab (AB154) in front-line, PD-L1-positive locally advanced or metastatic non-small cell lung cancer.

Key Eligibility Criteria

  • Histologically confirmed, squamous or nonsquamous, treatment-naive PD-L1 positive, NSCLC that is locally advanced or metastatic without sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation
  • Naive to any prior treatment with immune checkpoint blockade therapy

ARC-10 Clinical Trial Locations

clinicaltrials.gov

arrow

Non-Small Cell Lung Cancer, EGFRmut (ARC-4)

Overview

A Phase 1/1b open-label, dose-escalation and dose-expansion trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + carboplatin and pemetrexed, with or without zimberelimab in EGFR mutant non-small cell lung cancer.

Key Eligibility Criteria

  • Participants must have a sensitizing EGFR mutation and failed treatment with 1 TKI (or 1-2 TKIs for tumors with T790M mutation)
  • Previous treatment with chemotherapy or PD-1/PD-L1 therapy is not allowed

ARC-4 Clinical Trial Locations

clinicaltrials.gov

arrow